AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...
The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...
Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.
Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase ...
INR:4531. dr lottery sambad AstraZeneca's Imfinzi approved in Japan for first-line treatment of extensive-stage small cell lung cancer CDK4/6: First-in-Class wi ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback